| scholarly article | Q13442814 |
| P50 | author | Lesley D Schurman | Q56901184 |
| P2093 | author name string | Aron H Lichtman | |
| P2860 | cites work | Chronic traumatic encephalopathy in blast-exposed military veterans and a blast neurotrauma mouse model. | Q22242243 |
| Decompressive craniectomy for the treatment of refractory high intracranial pressure in traumatic brain injury | Q24244941 | ||
| Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain | Q24299523 | ||
| Brain monoglyceride lipase participating in endocannabinoid inactivation | Q24533828 | ||
| Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase | Q24555807 | ||
| Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker | Q24601670 | ||
| CB2 receptors in the brain: role in central immune function | Q24643895 | ||
| A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol | Q24649418 | ||
| Estradiol Decreases Cortical Reactive Astrogliosis after Brain Injury by a Mechanism Involving Cannabinoid Receptors | Q59341018 | ||
| A new perspective on cannabinoid signalling: complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain | Q64212085 | ||
| Diffuse axonal injury in head injury: definition, diagnosis and grading | Q69698410 | ||
| Fatty acid amide hydrolase substrate specificity | Q73324250 | ||
| Involvement of the cannabinoid CB2 receptor and its endogenous ligand 2-arachidonoylglycerol in oxazolone-induced contact dermatitis in mice | Q79401094 | ||
| Motor impairment after severe traumatic brain injury: A longitudinal multicenter study | Q80188117 | ||
| Neuroprotection and reduction of glial reaction by cannabidiol treatment after sciatic nerve transection in neonatal rats | Q39360618 | ||
| Recent Advances in the Chemistry of Hashish | Q39975059 | ||
| Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. | Q40440754 | ||
| N-oleoyldopamine, a novel endogenous capsaicin-like lipid that produces hyperalgesia | Q40672731 | ||
| Factors affecting excitatory amino acid release following severe human head injury | Q40840971 | ||
| Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors | Q40935207 | ||
| An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity | Q41012471 | ||
| Comparative neuroprotective effects of cyclosporin A and NIM811, a nonimmunosuppressive cyclosporin A analog, following traumatic brain injury | Q41774918 | ||
| O-Hydroxyacetamide Carbamates as a Highly Potent and Selective Class of Endocannabinoid Hydrolase Inhibitors | Q41971391 | ||
| Endocannabinoids modulate human blood-brain barrier permeability in vitro | Q42107964 | ||
| Statins increase neurogenesis in the dentate gyrus, reduce delayed neuronal death in the hippocampal CA3 region, and improve spatial learning in rat after traumatic brain injury | Q42384723 | ||
| Effect of rosuvastatin on amnesia and disorientation after traumatic brain injury (NCT003229758). | Q42439973 | ||
| Amplitude/frequency of spontaneous mEPSC correlates to the degree of long-term depression in the CA1 region of the hippocampal slice | Q42480403 | ||
| Does the neuroprotective role of anandamide display diurnal variations? | Q42769645 | ||
| Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration | Q43752352 | ||
| Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects | Q43846366 | ||
| Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial | Q43980213 | ||
| Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo | Q44028862 | ||
| Neuroscience. Stout guards of the central nervous system | Q44606611 | ||
| ‘Ischemic tolerance’ phenomenon detected in various brain regions | Q44805794 | ||
| Diffusion tensor imaging and volumetric analysis of the ventral striatum in adults with traumatic brain injury. | Q44815593 | ||
| Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. | Q44963304 | ||
| CB1 cannabinoid receptors are involved in neuroprotection via NF-kappa B inhibition | Q45281373 | ||
| Late mortality after severe traumatic brain injury in New South Wales: a multicentre study | Q46029334 | ||
| Pretreatment with electroacupuncture induces rapid tolerance to focal cerebral ischemia through regulation of endocannabinoid system | Q46048076 | ||
| Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy. | Q46123071 | ||
| The development of acute lung injury is associated with worse neurologic outcome in patients with severe traumatic brain injury | Q46193912 | ||
| 2-Arachidonoylglycerol, an endogenous cannabinoid receptor agonist, in various rat tissues during the evolution of experimental cholestatic liver disease | Q46389248 | ||
| Inhibition of Endocannabinoid Degradation Improves Outcomes from Mild Traumatic Brain Injury: A Mechanistic Role for Synaptic Hyperexcitability | Q46546882 | ||
| The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines | Q46859038 | ||
| CB1 receptor-mediated control of the release of endocannabinoids (as assessed by microdialysis coupled with LC/MS) in the rat hypothalamus | Q46871279 | ||
| A cannabinoid type 2 receptor agonist attenuates blood–brain barrier damage and neurodegeneration in a murine model of traumatic brain injury | Q47965888 | ||
| Accumulation of amyloid beta and tau and the formation of neurofilament inclusions following diffuse brain injury in the pig. | Q48105099 | ||
| Acute lung injury is an independent risk factor for brain hypoxia after severe traumatic brain injury. | Q48121266 | ||
| Guidelines for the management of severe traumatic brain injury. VIII. Intracranial pressure thresholds | Q48163500 | ||
| Guidelines for the management of severe traumatic brain injury. VI. Indications for intracranial pressure monitoring | Q48163517 | ||
| Guidelines for the management of severe traumatic brain injury | Q48163575 | ||
| Magnesium sulfate for neuroprotection after traumatic brain injury: a randomised controlled trial | Q48339039 | ||
| The early critical phase of severe head injury: importance of apnea and dysfunctional respiration | Q48348368 | ||
| The facilitating and suppressing effects of delta 9-tetrahydrocannabinol on the rise in intrasynaptosomal Ca2+ concentration in rats | Q48469786 | ||
| Sequential assessment of cerebral blood flow in diffuse brain injury by 123I-iodoamphetamine single-photon emission CT | Q48509294 | ||
| CB1 receptor antagonism prevents long-term hyperexcitability after head injury by regulation of dynorphin-KOR system and mGluR5 in rat hippocampus | Q48694375 | ||
| The biphasic opening of the blood-brain barrier in the cortex and hippocampus after traumatic brain injury in rats | Q48726066 | ||
| Cerebral blood flow as a predictor of outcome following traumatic brain injury | Q48742919 | ||
| Cannabidiol-treated rats exhibited higher motor score after cryogenic spinal cord injury | Q48900936 | ||
| Pre- and post-conditioning treatment with an ultra-low dose of Δ9-tetrahydrocannabinol (THC) protects against pentylenetetrazole (PTZ)-induced cognitive damage | Q51020105 | ||
| Voltage-gated sodium (NaV) channel blockade by plant cannabinoids does not confer anticonvulsant effects per se. | Q51749647 | ||
| Extent of microstructural white matter injury in postconcussive syndrome correlates with impaired cognitive reaction time: a 3T diffusion tensor imaging study of mild traumatic brain injury | Q51893033 | ||
| Long-Term Consequences of Severe Closed Head Injury on Episodic Memory | Q52015300 | ||
| Long-term effect of HU-211, a novel non-competitive NMDA antagonist, on motor and memory functions after closed head injury in the rat. | Q52209491 | ||
| Neurogenic pulmonary edema. Pathogenesis, clinical picture and therapy | Q54145722 | ||
| Synthetic cannabinoids. | Q55601191 | ||
| CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes | Q24649936 | ||
| A2A receptors in inflammation and injury: lessons learned from transgenic animals | Q24652486 | ||
| Human cannabinoid pharmacokinetics | Q24652736 | ||
| The orphan receptor GPR55 is a novel cannabinoid receptor | Q24670137 | ||
| Is posttraumatic epilepsy the best model of posttraumatic epilepsy? | Q24682111 | ||
| Hemopressin is an inverse agonist of CB1 cannabinoid receptors | Q24683759 | ||
| Chemical Probes of Endocannabinoid Metabolism | Q26863202 | ||
| Pathophysiology and neuroprotection of global and focal perinatal brain injury: lessons from animal models | Q27000069 | ||
| Chronic Posttraumatic Epilepsy following Neocortical Undercut Lesion in Mice | Q27335980 | ||
| Discovery and Characterization of a Highly Selective FAAH Inhibitor that Reduces Inflammatory Pain | Q27655121 | ||
| CB1 cannabinoid receptors and on-demand defense against excitotoxicity | Q28207143 | ||
| Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage | Q28214799 | ||
| Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor | Q28218654 | ||
| Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist | Q28262546 | ||
| Platelet‐ and macrophage‐derived endogenous cannabinoids are involved in endotoxin‐induced hypotension | Q28279865 | ||
| Phytocannabinoids beyond the Cannabis plant - do they exist? | Q28286497 | ||
| 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain | Q28290395 | ||
| Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors | Q28292914 | ||
| Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides | Q28295481 | ||
| Molecular characterization of a peripheral receptor for cannabinoids | Q28298338 | ||
| The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1) | Q28343961 | ||
| Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide | Q28370516 | ||
| Monoacylglycerol lipase (MAGL) inhibition attenuates acute lung injury in mice | Q28534648 | ||
| TRPV1 activation results in disruption of the blood-brain barrier in the rat | Q28577575 | ||
| Isolation and structure of a brain constituent that binds to the cannabinoid receptor | Q29547476 | ||
| The epidemiology and impact of traumatic brain injury: a brief overview | Q29615639 | ||
| Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study | Q29615905 | ||
| Determination and characterization of a cannabinoid receptor in rat brain | Q29618888 | ||
| Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord | Q29619388 | ||
| Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. | Q30492114 | ||
| Safety and tolerability of cyclosporin a in severe traumatic brain injury patients: results from a prospective randomized trial | Q33666525 | ||
| The palmitoylethanolamide and oleamide enigmas : are these two fatty acid amides cannabimimetic? | Q33724186 | ||
| Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol | Q33900859 | ||
| Endocannabinoids and vascular function. | Q33952765 | ||
| An endogenous cannabinoid (2-AG) is neuroprotective after brain injury | Q34093755 | ||
| Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels | Q36995471 | ||
| Using a cost-benefit analysis to estimate outcomes of a clinical treatment guideline: testing theBrain Trauma Foundation guidelines for the treatment of severe traumatic brain injury | Q37062826 | ||
| Targeting the endocannabinoid system: to enhance or reduce? | Q37150745 | ||
| Diglyceride lipase: a pathway for arachidonate release from human platelets | Q37336055 | ||
| Production and physiological actions of anandamide in the vasculature of the rat kidney. | Q37372676 | ||
| Complications of decompressive craniectomy for traumatic brain injury | Q37503188 | ||
| Neuropsychiatric Symptom Modeling in Male and Female C57BL/6J Mice after Experimental Traumatic Brain Injury | Q37649738 | ||
| Experimental models for analysis of oligodendrocyte pathophysiology in stroke | Q37691262 | ||
| Traumatic brain injury and amyloid-β pathology: a link to Alzheimer's disease? | Q37691554 | ||
| The epidemiology of traumatic brain injury | Q37710314 | ||
| Acute management of acquired brain injury part II: an evidence-based review of pharmacological interventions | Q37727119 | ||
| 150 years of treating severe traumatic brain injury: a systematic review of progress in mortality | Q37730854 | ||
| Supply and demand for endocannabinoids | Q37867227 | ||
| Blood-brain barrier pathophysiology in traumatic brain injury | Q37980746 | ||
| The Endocannabinoid System and the Brain | Q38026949 | ||
| The role of markers of inflammation in traumatic brain injury. | Q38086443 | ||
| Research progress in traumatic brain penumbra | Q38211502 | ||
| Effect of marijuana use on outcomes in traumatic brain injury | Q38255185 | ||
| The Role of the Brain's Endocannabinoid System in Pain and Its Modulation by Stress | Q38659962 | ||
| What are the disruptive symptoms of behavioral disorders after traumatic brain injury? A systematic review leading to recommendations for good practices | Q38697168 | ||
| Use of magnesium in traumatic brain injury | Q34096651 | ||
| CB2: a cannabinoid receptor with an identity crisis | Q34098185 | ||
| CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model | Q34098258 | ||
| Brain injury: the pathophysiology of the first hours.'Talk and Die revisited'. | Q34355155 | ||
| Moving around the molecule: relationship between chemical structure and in vivo activity of synthetic cannabinoids. | Q34373631 | ||
| Mechanical strain injury increases intracellular sodium and reverses Na+/Ca2+ exchange in cortical astrocytes | Q34374927 | ||
| Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial | Q34477439 | ||
| Synthetic Cannabinoids | Q34483121 | ||
| Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression | Q34651059 | ||
| The major central endocannabinoid directly acts at GABA A receptors | Q34660573 | ||
| Cannabinoid receptors and their ligands | Q34673022 | ||
| Endocannabinoid structure-activity relationships for interaction at the cannabinoid receptors | Q34673044 | ||
| The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors | Q34792462 | ||
| Thematic Review Series: Proteomics. An integrated omics analysis of eicosanoid biology | Q34952213 | ||
| Detection of behavioral alterations and learning deficits in mice lacking synaptophysin. | Q34977739 | ||
| Ischemic tolerance and endogenous neuroprotection | Q35126696 | ||
| Endocannabinoid degradation inhibition improves neurobehavioral function, blood-brain barrier integrity, and neuroinflammation following mild traumatic brain injury | Q35143425 | ||
| Inhibition of monoacylglycerol lipase prevents chronic traumatic encephalopathy-like neuropathology in a mouse model of repetitive mild closed head injury. | Q35143497 | ||
| The dual neuroprotective–neurotoxic profile of cannabinoid drugs | Q35193273 | ||
| Similarities and differences in spatial learning and object recognition between young male C57Bl/6J mice and Sprague-Dawley rats | Q35275747 | ||
| A mouse model of blast-induced mild traumatic brain injury. | Q35449811 | ||
| The neurophysiology of brain injury | Q35620865 | ||
| The fatty acid amide hydrolase inhibitor PF-3845 promotes neuronal survival, attenuates inflammation and improves functional recovery in mice with traumatic brain injury | Q35624344 | ||
| Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation | Q35645037 | ||
| Cell death mechanisms following traumatic brain injury | Q35802485 | ||
| An integrated approach to prevent and treat respiratory failure in brain-injured patients | Q36014168 | ||
| Oxidative stress in the brain: novel cellular targets that govern survival during neurodegenerative disease | Q36121400 | ||
| The effect of moderate to severe traumatic brain injury (TBI) on different aspects of memory: a selective review | Q36278289 | ||
| Endocannabinoid regulation of nausea is mediated by 2-arachidonoylglycerol (2-AG) in the rat visceral insular cortex | Q36421863 | ||
| Mechanisms of CB1 receptor signaling: endocannabinoid modulation of synaptic strength. | Q36434427 | ||
| Cerebral preconditioning and ischaemic tolerance | Q36484538 | ||
| Human lung-resident macrophages express CB1 and CB2 receptors whose activation inhibits the release of angiogenic and lymphangiogenic factors | Q36676002 | ||
| Selective Inhibition of Alpha/Beta-Hydrolase Domain 6 Attenuates Neurodegeneration, Alleviates Blood Brain Barrier Breakdown, and Improves Functional Recovery in a Mouse Model of Traumatic Brain Injury | Q36795890 | ||
| P921 | main subject | traumatic brain injury | Q1995526 |
| endocannabinoids | Q10483908 | ||
| P304 | page(s) | 69 | |
| P577 | publication date | 2017-02-17 | |
| P1433 | published in | Frontiers in Pharmacology | Q2681208 |
| P1476 | title | Endocannabinoids: A Promising Impact for Traumatic Brain Injury | |
| P478 | volume | 8 |
| Q89546933 | Cannabis Use and Sport: A Systematic Review |
| Q90259463 | Cannabis in the Treatment of Traumatic Brain Injury: A Primer for Clinicians |
| Q57177300 | Chemical Proteomic Analysis of Serine Hydrolase Activity in Niemann-Pick Type C Mouse Brain |
| Q101051220 | Conformational gating, dynamics and allostery in human monoacylglycerol lipase |
| Q38747752 | Elucidating opportunities and pitfalls in the treatment of experimental traumatic brain injury to optimize and facilitate clinical translation. |
| Q52583978 | INSIGHT ON THE IMPACT OF ENDOCANNABINOID SYSTEM IN CANCER: A REVIEW. |
| Q99350059 | Low brain endocannabinoids associated with persistent non-goal directed nighttime hyperactivity after traumatic brain injury in mice |
| Q89945819 | Medical Cannabis Reduced Agitation in Acquired Brain Injury: A Case Study |
| Q58102489 | Medical Use of Cannabinoids |
| Q96576962 | Multicellular 3D Neurovascular Unit Model for Assessing Hypoxia and Neuroinflammation Induced Blood-Brain Barrier Dysfunction |
| Q89579808 | Neuroprotection Following Concussion: The Potential Role for Cannabidiol |
| Q57157638 | Neurotransmitter changes after traumatic brain injury: an update for new treatment strategies |
| Q64108699 | Oral Cannabidiol Prevents Allodynia and Neurological Dysfunctions in a Mouse Model of Mild Traumatic Brain Injury |
| Q55439675 | Review of the neurological benefits of phytocannabinoids. |
| Q99553751 | Understanding Cannabis-Based Therapeutics in Sports Medicine |
Search more.